503A compounding pharmacy.

A pharmacy that prepares customized medications for individual prescriptions.

Section 503A of the United States Federal Food, Drug, and Cosmetic Act describes traditional compounding pharmacies, which prepare customized medications for an identified individual patient in response to a specific prescription. Legitimate reasons include a patient's allergy to an ingredient in the commercial product, a need for a different strength or dosage form, or a shortage of the manufactured drug. Compounded preparations are not FDA-approved: the agency does not review them for safety, effectiveness, or manufacturing quality, and they are overseen primarily by state boards of pharmacy. Section 503B outsourcing facilities are the separate, more heavily regulated category permitted to produce larger batches without individual prescriptions. This distinction became widely relevant when demand for GLP-1 receptor agonists outstripped supply and compounded versions proliferated. The points worth understanding are specific. Compounding law restricts the use of bulk active ingredients and generally does not permit copying a commercially available approved drug. Compounded products may differ from the approved product in salt form, concentration, or excipients, meaning they are not established equivalents. And a compounded preparation carries none of the manufacturing oversight, batch surveillance, or approved labelling of the product it resembles, which is a genuine difference in the safety infrastructure behind it.